BGI-East China covers Jiangsu Province, Zhejiang Province, Fujian Province, Shandong Province and Shanghai, representing the most comprehensively developed region in China on technology, economy, and culture.
BGI Hangzhou, BGI Shanghai and BGI Nanjing were established respectively.
So far, BGI-East China has formed collaborations with more than 70 institutions. Business involves genetic testing for reproductive health, cancer, hereditary diseases disease, pathogenic microorganism detection, and etc.
|BGI Shanghai||BGI Hangzhou||BGI Nanjing|
BGI Shanghai will use genome sequencing and information analysis as core competitiveness, to achieve the application of genomics in medical health, as well as expand the scale of industry in East China.
BGI Hangzhou has achieved a significantly higher visibility in DNA sequence analysis and is developing towards setting up National Bio-industries with independent intellectual property rights.
BGI Nanjing is located in the southwest of Nanjing and serves as the hub for the Yangtze River Delta area and for promoting the development of central and western areas of China. BGI Nanjing diligently strives to promote the transformation of genomic, scientific and technological achievements into applications.
|Jan 21, 2001||In the support from the government of Hangzhou city and Zhejiang province, “BGI Hangzhou gene R&D center” was established|
BGI Sanger sequencing platform officially stationed in Shanghai, started to provide Sanger sequencing service for research institutions of Shanghai, Jiangsu, Shandong and Fujian.
|Dec 13, 2010||BGI signed a cooperation framework agreement with Shanghai International Medical Zone (SIMZ) in Hong Kong.|
|May 2011||BGI Shanghai technology co., LTD, was formally registered.|
|Sept 15, 2011||BGI Nanjing technology co., LTD, was formally registered and established.|
|Nov 11, 2011||BGI Shanghai opening ceremony was held at Shanghai century med care park, BGI started a new journey in east China.|
|January 31, 2012||BGI Nanjing technology co., LTD. signed a cooperation agreement with the Management Committee of Nanjing Newtown Science & Technology Park, reached an agreement that BGI Nanjing would be settled in Jianye district.|
|August 16, 2012||BGI Nanjing medical institute obtained approval for establishment of medical institution.|
|2012||BGI Shanghai medical examination center was established, in the same year on December 31, Shanghai municipal health bureau approved and certified the Practicing License of Medical Institution.|
|July 4, 2013||BGI Nanjing medical institute was checked and accepted by Nanjing health supervision bureau, permitted to practice as a medical institute.|
Predominant geographical location: It is in the frontier regions of China where the biotechnology industry is in higher development.
Abundant customer resources: There are many well-known pharmaceutical factories, universities, hospitals, with huge potential for development.
Professional team and innovative team work.
BGI Hangzhou is the earliest established R&D center of BGI, with the most senior technical personnel of research and development.
On June 3, 2012, “National GeneBank - Wuxi Tumor Bank” was launched.
On June 11, 2012, BGI cooperated with Wuxi Maternal and Child Health-Care Hospital on Non-Invasive Prenatal Genetic Testing of Fetal Chromosomal Aneuploidy, Genotyping Test of Human Papillomavirus (HPV) and Genetic testing of monogenic diseases. The project has screened 13,000 cervical cancer screening samples and 4,000 Non-Invasive Prenatal Genetic Testing (NIPT) samples.
On March 12, 2012, BGI cooperated with Weifang Family Planning Committee on birth defects testing. It has completed about 1500 Non-Invasive Prenatal Genetic Testing (NIPT) at present.
On November 25, 2012, National GeneBank signed a strategic cooperation memorandum with the Centers for Disease Control and Prevention of Minhang District, to establish a joint biobank.
On February 3, 2013, BGI signed a strategic cooperation framework agreement with the Second Military Medical University to establish a translational medicine laboratory, carry out clinical & research projects in tumor.
On February 6, 2013, BGI signed cooperative agreement with Jining Maternal and Child Health-Care Hospital. Non-Invasive Prenatal Genetic Testing (NIPT) was listed in ten focused project of Jining government in 2013.
On April 28, 2013, In late May 2013, HPV screening project was launched in Minhang District of Shanghai .
- [news]CFDA Approved Next Generation Sequencing Diagnostic Products
- [news]BGI announces world-leading research centre with the University of Birmingham
- [news]Four BGI Researchers Listed as Thomson Reuters’ Highly Cited
- [news]BGI Ranked 5th of NPI 2013 Top 10 Chinese Institutions
- [news] BGI Listed as Fast Company’s 2014 World’s 50 Most Innovative Companies
- [news]BGI Ranked 119 of Global Top 200 Scientific Institutions in 2012
BGI North China
Address: Building C2-2/3, R& Dcenter, Shiqiaozi Mulan Road, High-tech Zone, Benxi, Liaoning Province, 117004, China
BGI East China
BGI Central China
Address: No. 389 Haiyuan Road, High-tech Development Zone, Kunming, Yunnan, 650106, China
BGI Northwest China
Address(Prepared): Administration Building, No. 6 Xinqiao Road, Yangling District, Xi’an, Shanxi, 712100, China
BGI South China
BGI TibetAddress: No. 189, Jinzhu West Road, Lhasa, 850000, China